• DOMA Perpetual Capital Management, which holds about 7.5% of Pacira, urged shareholders to vote for its three board nominees using its white proxy card ahead of the June 9, 2026 annual meeting.
• The activist criticized CEO Frank Lee and the board for sustained underperformance, citing price-only total shareholder return of -64% over five years and -28% since Lee became CEO.
• DOMA argued the company is taking outsized legal risk by pursuing further EXPAREL patent litigation, warning another adverse ruling could be catastrophic without a contingency plan.
• The fund pushed for a board-supervised review of strategic alternatives, including a potential sale, framing it as the “safest” path to protect shareholder value.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605211353PR_NEWS_USPR_____FL65610) on May 21, 2026, and is solely responsible for the information contained therein.